TrialSiteNews

Join The Conversation! | https://trialsitenews.com/ Professor Dimitry Kochenov discusses Vaccine Passports with Erin Stair. Dimitry Kochenov "The Passport Professor" is an expert on citizenship, constitutionalism and nationality law who held a chair in European Constitutional law and Citizenship at the University of Groningen. Relevant links | http://kochenov.eu/ Papers discussed in the podcast: The Commission against the Internal Market and European Union Citizens’ Rights: Trying to Shoot Down Sputnik with the “Digital Green Certificate”? The Commission against the Internal Market and European Union Citizens’ Rights: Trying to Shoot Down Sputnik with the “Digital Green Certificate”? | European Journal of Risk Regulation | Cambridge Core And A Terrible Great Idea: Vaccination Passports | https://www.compas.ox.ac.uk/wp-content/uploads/WP-2021-153-Gstrein-Kochenov-Zwitter-A-Terrible-Great-Idea-Vaccination-Passports.pdf

Join The Conversation! | https://trialsitenews.com/ Dr. Robert Malone to discusses the rise in medical censorship both here in the US, and abroad.

Join The Conversation! | https://trialsitenews.com/ Dr. Kevin Murphy discusses PrTMS and how it is used to treat a wide variety of neurological, mental & physical health issues. https://www.prtms.com/

Join The Conversation! | https://trialsitenews.com/ Alexis Mclaughlin discusses On-Site2020, mobile eye exams and inherited retinal disease.

Join The Conversation! | https://trialsitenews.com/ Dr. Robert Malone, Inventor of mRNA technology discusses the Spike Protein. Dr. Erin Stair discusses with Dr. Robert Malone about the COVID-19 Spike Protein vs the Spike Protein produced by the COVID-19 Vaccines and more. Referenced Articles: Salk Institute Paper | https://www.salk.edu/news-release/the-novel-coronavirus-spike-protein-plays-additional-key-role-in-illness/ Canadian physicians FOIA | https://trialsitenews.com/did-pfizer-fail-to-perform-industry-standard-animal-testing-prior-to-initiation-of-mrna-clinical-trials/ Reuters Fact Check | https://www.reuters.com/article/factcheck-vaccine-safe/fact-check-no-evidence-spike-proteins-from-covid-19-vaccines-are-toxic-idUSL2N2NX1J6 Circulating SARS-CoV-2 Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients | https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab465/6279075

Join The Conversation! | https://trialsitenews.com/ WHO Eyes ‘Protecting’ Ivermectin from Use for COVID as It Plans to Emerge Out of Pandemic & Refocus on NTD Programs: Recently, the World Health Organization (WHO) conducted its 14th meeting of the Strategic and Technical Advisory Group for Neglected Tropical Diseases (NTD), held virtually from June 22 to June 24, 2021. Known as STAG (Strategic and Technical Advisory Group), the group published a number of recommendations, including the potential implications of COVID-19 on Neglected Tropical Diseases. Article Link | https://trialsitenews.com/who-eyes-protecting-ivermectin-from-use-for-covid-as-it-plans-to-emerge-out-of-pandemic-refocus-on-ntd-programs/ Who is Declaring What’s Legitimate Information vs. Misinformation on Wikipedia? Wikipedia purports to be an objective, non-biased online knowledge repository seeking to “create and distribute a free encyclopedia of the highest possible quality to every single person on the planet in their own language.” Undoubtedly, that information should be truthful and as unbiased as possible. For those tracking the ivermectin studies during the pandemic, Wikipedia is starting to look anything but unbiased. Article Link | https://trialsitenews.com/who-is-declaring-whats-legitimate-information-vs-misinformation-on-wikipedia/

Join The Conversation! | https://trialsitenews.com/ Dr. Erin Stair talks with Dr. Sabine Hazan about the Microbiome, her research, and the Covid-19 genetic sequence found in stool samples. Dr. Sabine Hazan Bio: https://www.venturaclinicaltrials.com/sabine-hazan-md/

Join The Conversation! | https://trialsitenews.com/ Dr. Monica Gandhi talks Covid-19, Delta Variant and Vaccination Safety for Kids. Dr. Monica Gandhi Bio | Monica Gandhi MD, MPH is Professor of Medicine and Associate Division Chief (Clinical Operations/ Education) of the Division of HIV, Infectious Diseases, and Global Medicine at UCSF/ San Francisco General Hospital. She also serves as the Director of the UCSF Center for AIDS Research (CFAR) and the Medical director of the HIV Clinic at SFGH ("Ward 86"). Dr. Gandhi completed her M.D. at Harvard Medical School and then came to UCSF in 1996 for residency training in Internal Medicine. After her residency, Dr. Gandhi completed a fellowship in Infectious Diseases and a postdoctoral fellowship at the Center for AIDS Prevention Studies, both at UCSF. She also obtained a Masters in Public Health from Berkeley in 2001 with a focus on Epidemiology and Biostatistics. Link to bio page: https://profiles.ucsf.edu/monica.gandhi

Join The Conversation! | https://trialsitenews.com/ FDA Issues Warning to Consuming Public About mRNA-based Vaccines: Higher Risk for Heart Inflammation: As reported by a number of major media outlets recently, the U.S Food and Drug Administration (FDA) moved forward to include a warning concerning for the Moderna and Pfizer-BioNTech Covid-19 vaccines, regarding the suggested increased risks of myocarditis (or, inflammation of the heart muscle, and pericarditis (inflammation of the tissue surrounding the heart, following vaccination. Article Link | https://trialsitenews.com/fda-to-issue-warning-to-consuming-public-about-mrna-based-vaccines-higher-risk-for-heart-inflammation/ Ivermectin Authorized in Indonesia as Pharma Issued License for Production to Battle COVID-19: Indonesia’s now in the middle of its most severe wave of the COVID-19 pandemic. Now thanks in part to a wealthy entrepreneur presently serving as the Minister for State Owned Enterprises (SOE), the country’s national drug regulator authorized the use of ivermectin on an off-label basis targeting COVID-19. In 2020, the Indonesian government brought in a wealthy, dynamic, and aggressive businessman to shake up and turn around state-owned enterprises known as “SOE.” Now they’ve turned Erick Thohir loose on COVID-19, and there’s nothing but business. A pragmatic yet big thinker, the new SOE Minister of the Food and Drug Supervisory Agency, known for the acronym BPOM, issued a distribution permit for ivermectin, meaning the regulatory body for this Southeast Asian nation of 270 million, the worlds’ fourth most populous nation, has authorized the use of the generic, low-cost drug as a therapeutic for COVID-19. Based on the results of a study, this BPOM action led to a distribution license to PT Indofarma Tbk; and production now has commenced with plans for distribution of over 4 million units per month. Article Link | https://trialsitenews.com/ivermectin-authorized-in-indonesia-as-pharma-issued-license-for-production-to-battle-covid-19/

Join The Conversation! | https://trialsitenews.com/ Dr. Luis Garegnani from Argentia wrote an opinion piece on Ivermectin not having enough evidence behind it in BMJ Journals. Dr. Pierre Kory of the FLCCC disagrees. Both doctors debate this issue with Dr. Erin Stair as the moderator. About Luis Garegnani: Luis Garegnani is a Professor of Research methods and evidence-based medicine at Instituto Universitario del Hospital Italiano de Buenos Aires. He is also a Physical Therapist from Universidad de Buenos Aires (UBA), specializing in Respiratory Critical Care and Mechanical Ventilation. He is a Research Fellow at Instituto Universitario del Hospital Italiano Cochrane Associate Centre since 2018 and currently an Associate Editor for the peer-reviewed BMJ Evidence-Based Medicine Journal. See Article Written by Dr. Louis Garegnani | https://ebm.bmj.com/content/early/2021/05/26/bmjebm-2021-111678 About Pierre Kory: Founding member of the FLCCC Alliance and co-author of the MATH+ and I-MASK+ Prophylaxis and Treatment Protocols for Covid-19

Join The Conversation! | https://trialsitenews.com/ Article 1 | UK-based Meta Analysis Peer Reviewed & Published Suggests Ivermectin A Key Public Health Weapon in the War Against COVID-19: Recently published in the peer-reviewed American Journal of Therapeutics, Dr. Tess Lawrie, an expert in medicinal evidence, along with other experts in population health and gastroenterology out of the United Kingdom (UK), conducted a comprehensive meta-analysis involving the certainty of evidence using an approach known as GRADE, which led to the focus on twenty-four ivermectin-centered randomized controlled trials involving 3,406 participants. Article Link | https://trialsitenews.com/uk-based-meta-analysis-peer-reviewed-published-suggests-ivermectin-a-key-public-health-weapon-in-the-war-against-covid-19/ Article 2 | Breaking News Novavax’ Traditional Vaccine Brings Imminent Competition to the Genetic-based Vaccines Currently Under EUA: U.S-based Novavax (Nasdaq: NVAX) reports today that its COVID-19 vaccine candidate called NVX-CoV2373 or “Coronavax” demonstrated 100% protection against moderate and severe disease and 90.4% overall efficacy, keeping this investigational product competitive with both mRNA-based vaccine products under emergency use authorization (EUA) as well as superior to the Johnson and Johnson Adenovirus-based vaccine, which is also authorized for deployment in the USA on an emergency basis. Article Link | https://trialsitenews.com/breaking-news-novavax-traditional-vaccine-brings-imminent-competition-to-the-genetic-based-vaccines-currently-under-eua/

Join the Conversation! | https://trialsitenews.com/ Article 1 | DGHS Hatchet Chops Ivermectin Nationally While Positioning Unproven Tocilizumab Despite Success of Uttar Pradesh—How will ICMR & AIMS Weigh In? In India it appears that as quickly as select national health authorities included ivermectin in the national guidelines, so too, has the recommendation just as been rescinded despite what appears to be tremendous success in states such as Uttar Pradesh. Article Link | https://trialsitenews.com/dghs-hatchet-chops-ivermectin-nationally-while-positioning-unproven-tocilizumab-despite-success-of-uttar-pradesh-how-will-icmr-aims-weigh-in/ Article 2 | After $356M in Federal Funds in Dec, Merck Secures $1.2B Federal Commitment to Buy its Experimental Drug Upon Key Milestones In an interesting case that has some suggesting brilliant corporate enterprising business prowess while critics suggest it is an example of crony capitalism on display… Merck has recently announced it secured a $1.2 billion public commitment for up to $1.7 million courses of its still experimental antiviral drug Molnupiravir to the United States government. Article Link | https://trialsitenews.com/after-356m-in-federal-funds-in-dec-merck-secures-1-2b-federal-commitment-to-buy-its-experimental-drug-upon-key-milestones/

Join the Conversation! | https://trialsitenews.com/ In the first edition of CATalyst, Shabnam Palesa Mohamed engages Advocate Dipali Ohja (IBA), Dr Pierre Kory (FLCCC), and Dr Tess Lawrie (EBMC) about the Indian Bar Association's decision to issue legal notice on WHO chief scientist, Dr Soumya Swaminathan. The 51 page notice, served 25th of May, claims as its legal basis alleged WHO's 'disinformation and censorship' on the Ivermectin issue. #CATalyst #TrialSiteNews #TrialSiteNewsAfrica #TSNA

Join the Conversation! | https://trialsitenews.com/ Mumbai Move for Ivermectin Prophylaxis While Uttar Pradesh Smashes COVID-19: With ivermectin now on the national Indian COVID-19 list of recommended treatments for COVID-19, a few states have gone to the next level and included the low-cost, generic drug approved throughout the world as a parasite fighter as a prophylactic targeting SARS-CoV-2, the virus behind COVID-19. Three Indian states, including Goa, Karnataka and Uttarakhand, have authorized ivermectin as a prophylaxis along with vitamin D during the pandemic. Article Link | https://trialsitenews.com/mumbai-move-for-ivermectin-prophylaxis-while-uttar-pradesh-smashes-covid-19-but-drugs-use-suppressed-in-media/ Indian Bar Association Serves Legal Notice Upon Dr. Soumya Swaminathan, the Chief Scientist, WHO: Dr. Soumya Swaminathan, the Chief Scientist at the World Health Organisation (WHO), was apparently served a legal notice by Indian Bar Association (IBA) on May 25, 2021, for her alleged act of spreading disinformation and thus misleading the people of India, in order to fulfill her own agenda, so the plaintiff’s action declares. Article | https://trialsitenews.com/indian-bar-association-serves-legal-notice-upon-dr-soumya-swaminathan-the-chief-scientist-who/

Join The Conversation! | https://trialsitenews.com/ Unprecedented Pandemic Turnaround in Uttar Pradesh with Dramatic Decline in Cases The health authorities for the state of Uttar Pradesh are easing up on COVID-19-based restrictions, at least in zones of the state where SARS-CoV-2 infections now fall below 600 cases. The state was already offering ivermectin as part of a population-wide regimen but the health authorities there doubled down their efforts as India’s national COVID-19 guidelines introduced ivermectin just days before. Article Link | https://trialsitenews.com/unprecedented-pandemic-turnaround-in-uttar-pradesh-with-dramatic-decline-in-cases-time-to-smell-the-coffee/ Story 2 | University of Minnesota ‘COVID-OUT’ Factorial Trial Investigates Potential of Ivermectin, Fluvoxamine & Metformin for Early Onset Mild-to-Moderate COVID-19 The University of Minnesota recently added generic study drugs to critically important yet not widely known clinical trial investigating outpatient treatment for SARS-CoV-2 infection, the virus behind COVID-19. The study, led by Carolyn Bramante called The COVIDOUT clinical trial targets an incredibly important segment of the COVID-19 diseases spectrum, which covers approximately 90% of the total cases that fall in either the asymptomatic or mild-to-moderate symptomatic category. At Present, there are no authorized treatments for this massive population. While a few pharmaceutical companies, such as Merck and Pfizer as well as AstraZeneca, are testing therapies that target this lucrative market, around the world other generic drugs are either under investigation or are in use such as Ivermectin, Favipiravir, and others. Article Link | https://trialsitenews.com/university-of-minnesota-covid-out-factorial-trial-investigates-potential-of-ivermectin-fluvoxamine-metformin-for-early-onset-mild-to-moderate-covid-19/

Join The Conversation! | https://trialsitenews.com/ We are thrilled to announce the release of the new TrialSite app. With over 70% of people reading TrialSite News from a mobile device, this is an important next step in our goal of connecting the clinical research community around the globe. Features of the app: Latest news and analysis of clinical research Enhanced commenting and usability Groups, forums and discussions Connection with other community members The app is free to download and is available for both IOS and Android phones. iOS App Link: https://apps.apple.com/us/app/trialsite/id1565856630 Google Play Link: https://play.google.com/store/apps/details?id=com.trialsitenews.trialsite

Join The Conversation! | https://trialsitenews.com/ Join us for the first part in a multi-part interview with Dr. Breggin who discusses his upcoming book "Covid-19 and the Global Predators: We Are The Prey", which covers the origins of Covid-19, including accusations of misuse of science. Pre-Order The Book | https://www.wearetheprey.com/ Dr. Breggin Website | https://breggin.com/ "This book is a must-read-now-to-understand what is happening before our very eyes. Sit forward, with both feet on the ground and be ready for the most gripping nonfiction that just rocketed into your library. What you will learn may save you and your family in the turbulent times ahead." Peter A. McCullough MD, MPH

Join The Conversation! | https://trialsitenews.com/ Story 1 | Mexico City Wide Innovative Population-Level Study Administers Ivermectin-based Home Kits with Drastic Reduction in Hospitalizations Since December 28, the ivermectin-based medical kits were distributed to mild to moderate symptomatic patients. The Mexico City Government sought to measure the effectiveness o f this population-wide intervention inclusive of the ivermectin-based medical kit in overall hospitalization during the pandemic. Using a quasi-experimental research design involving a Coarsened Exact Matching method leveraging hospital and phone call monitoring data, the study team estimated logistic-regression models with a range of observational data and found a significant reduction in hospitalizations among the cohort receiving ivermectin-based medical kit. Story Article: https://trialsitenews.com/mexico-city-wide-innovative-population-level-study-administers-ivermectin-based-home-kits-with-drastic-reduction-in-hospitalizations/ Story 2 | Uttar Pradesh Health Officials on Record: Claims Ivermectin as Prophylactic Has Lowered COVID-19 Infection Rate & Death Rate The government of Uttar Pradesh, the most populated state in India, has declared that the use of Ivermectin as a “Prophylactic and therapeutic” has not only lowered transmission and infection rates but has also served to reduce the COVID-19 death rate as well. It’s been a year since the first cluster of five (5) cases was reported in Agra, and recently, the Health Department has shared positive results with the ongoing program. TrialSite shared August last year that the most populated Indian state embraced Ivermectin as a COVID-19 therapy and prophylactic while no Western press bothered to touch the subject. More recently, TrialSite reported that ivermectin has been included in the national COVID-19 guidance due in part to positive outcomes now emerging. Again, there hasn’t been a peep from the West. Uttar Pradesh was an early mover, embracing a protocol using both the anti-parasite drug as well as Doxycycline for use as a prophylactic and as a therapeutic tool targeting COVID-19. Clinical trials in Bangladesh using a similar protocol were producing results last summer as well. Now the Uttar Pradesh health department shared recently that it also plans on conducting a controlled study once this second wave of the pandemic wanes. Story Article: https://trialsitenews.com/uttar-pradesh-health-officials-on-record-ivermectin-as-prophylactic-has-lowered-covid-19-infection-rate-death-rates/

Dr. Tom Pitts Discusses Mutiple Sclerosis: Symptoms, And the Treatment Landscape for the disease and answers your questions. Join The Conversation! https://trialsitenews.com/

How 2 Companies Are Streamlining Patient Recruitment For Clinical Trials. Join The Conversation! https://trialsitenews.com Reify Health | https://www.reifyhealth.com/ SubjectWell | https://www.subjectwell.com/ TrialSite News | https://trialsitenews.com/ Join us for a discussion with Ralph Passarella of Reify Health, and Ivor Clarke of SubjectWell as we talk about Streamlining Patient Recruitment for Clinical Trials. A fascinating look into the world of Clinical Trials!

Covid-19 Outbreak in India: Initial Review of the Data and the India Solution. Join The Conversation! https://trialsitenews.com So, The whole world has been watching India lately. Just a matter of months ago, India’s cases and fatalities were few and now, an explosion of cases through out the country… so, What happened here? And, what is the solution for outbreak? We discuss! Story Article: https://trialsitenews.com/the-outbreak-in-india-initial-review-of-the-data/

Tom Pitts Discusses Mayasthenia Gravis: Symptoms, and the treatment landscape. Join The Conversation! https://trialsitenews.com

John W. Swanson, an 81-year-old farmer from Stafford, New York, a rural area east of Buffalo, was infected with COVID-19, on a ventilator, and according to a legal affidavit, ‘on death’s doorstep’ at United Memorial Medical Center (part of Rochester Regional Health). The patient was given one dose of ivermectin, and started breathing again. But in what is becoming a similar New York State story, the hospital’s doctors then refused to give follow-up doses of ivermectin. And the patient’s family moved swiftly for justice. Swanson’s wife Sandra hired the same attorneys that were able to convince other New York State judges to compel other hospitals to administer ivermectin to dying patients. Story Article: https://trialsitenews.com/another-new-york-state-supreme-court-justice-ivermectin-order-helping-81-year-old-farmer/ Reminder: We here at TrialSite News always recommend seeking advice from a physician for treatment in regards to Covid-19. Additionally as of the filming of this episode, here in the US the official guidelines from the FDA and the NIH are as follows. First, The FDA has cautioned against its use for Covid-19 saying that they have not approved ivermectin for use in treating or preventing COVID-19 in humans. The FDA also added a notice about the use of the animal version of Ivermectin saying that one should “Never use medications intended for animals on yourself. Ivermectin preparations for animals are very different from those approved for humans.” Second, The NIH has a softer stance on the subject of Ivermectin, with a more neutral stance, neither for, nor against the use of the drug.

Ian Chan of Abpro, addresses the important conversation about Covid-19 treatments and the race to catch up to mutant variants. The Boston based biotech Abpro Therapeutics is developing a monoclonal antibody treatment called ADP 300 that may be effective even in people infected with one of these new strains. This, according to pre-clinical data that the company published in nature communications. You can find out more about Abpro by following the link here: https://abpro.com/ For more on this and related topics, visit www.trialsitenews.com to join the conversation!

Article 1 Texas Physician/Researchers Case Series Finds Reduction in COVID-19 Hospitalization by 87.6% & Death 74.9%: A group of Texas-based providers, including physicians, some highly published, recently published in the International Journal of Innovative Research in Medical Science results of a case series type of study initially involving a group of 320 COVID-19 patients deemed high risk—which is to says, over 50 years old with at least one comorbidity. The group was then able to add 549 cases more by the end of the study period, which was December of 2020. This group of physicians, who are part of a small but vocal and dedicated camp, declared that during the pandemic, the medical profession disappointed, turning into “watchful watchers” for the vast majority of COVID-19 cases—especially they claimed, those cases that fit the study patient category—desperately needing care. Original Article Link: https://trialsitenews.com/texas-physician-researchers-case-series-finds-reduction-in-covid-19-hospitalization-by-87-6-death-74-9/ Article 2 Ivermectin Proponents Celebrate South African Court Victory: The civil rights organization AfriForum and Dr George Coetzee today achieved a further success in the South African struggle for access to the antiparasitic drug ivermectin off-label for the indication of SARS-CoV-2, the virus behind COVID-19. TrialSite has covered this unfolding legal saga with far reaching societal implications, when the settlement for the compounding of and access to ivermectin with the South African Health Products Regulatory Authority (SAHPRA) was made an order of court. Original Article Link https://trialsitenews.com/ivermectin-proponents-celebrate-south-african-court-victory/